Zelnorm (tegaserod maleate) is a drug to treat constipation symptoms in women with irritable bowel syndrome (IBS) on a short-term basis and to treat chronic idiopathic constipation. It first came on the market in 2002 when the Food and Drug Administration (FDA) approved it for the treatment of IBS.
Zelnorm is Removed from U.S. Market
In March 2007, the FDA requested that Novartis Pharmaceuticas, the manufacturer of Zelnorm, remove the drug from the U.S. market. Novartis agreed and the removal was immediately effective. The Zelnorm claim is that it increases the movement of stools through the bowels and may reduce abdominal pain and discomfort, bloating, and constipation. It does not claim to cure IBS, to work for all women, or to be effective in treating IBS in men.
Zelnorm, Diarrhea and Reduced Blood Flow to Intestines
By 2004, the FDA had required new labeling to warn of potential Zelnorm side effects of diarrhea and reduced blood flow to the intestines. Both of these side effects can have serious complications. Diarrhea may cause dehydration that can require hospitalization and low blood pressure. A decrease in blood flow to the intestines can cause serious injury to the intestines and even death. See Drug Warning: Zelnorm Side Effects and Risks.
Zelnorm and Heart Attacks, Strokes, and Angina
In March 2007, the FDA reviewed a new analysis of 29 studies of people using Zelnorm. The new analysis of these studies showed that people taking Zelnorm are statistically more likely to have heart attacks, strokes, or angina (severe chest pain). Because of the serious nature of these potential Zelnorm side effects, the FDA ordered it off the U.S. market immediately. See Zelnorm Information and Warnings for more information about the studies.
More Articles
Check out the following articles for more information about Zelnorm, filing a Zelnorm lawsuit and finding a Zelnorm attorney.